Werewolf Therapeutics Q1 EPS $(0.34) Beats $(0.50) Estimate, Sales $4.46M Miss $5.00M Estimate; Cash Balance Of $129.3M Provides Cash Runway Into Q4 Of 2024

Benzinga · 05/11/2023 11:12
Werewolf Therapeutics (NASDAQ:HOWL) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.50) by 32 percent. This is a 39.29 percent increase over losses of $(0.56) per share from the same period last year. The company reported quarterly sales of $4.46 million which missed the analyst consensus estimate of $5.00 million by 10.72 percent.